Skip to main content
StrykerInvestment

Stryker invests $400m in CMR Surgical - and could buy the rest

Source: Autobound Signal API · 121 signals tracked for Stryker · updated

Get Stryker's live signals in Claude or ChatGPT, or by API

AskWhat changed at Stryker this week? Use Autobound signals for stryker.com.

What happened

Stryker invested $400 million in CMR Surgical to acquire exclusive US commercial rights to the Versius surgical robotic portfolio, along with an option to buy the remaining equity.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

Multinational US medical technologies company Stryker has invested $400million in the acquisition of exclusive US commercial rights to CMR Surgical's Versius portfolio - with a further exclusive option to acquire the remaining equity at a later date. The sensational alliance means CMR Surgical's established platform and robotics expertise will align with Stryker's scale, customer relationships and commercial reach to accelerate growth of its Versius surgical robotic portfolio. The minority investment - CMR's last official valuation was for $3billion in 2021 during a $600m Series D funding round led by SoftBank and Ally Bridge - means Stryker will serve as the exclusive US sales agent for the Versius portfolio, while CMR Surgical will continue to lead portfolio development and commercialisation in non-US markets. The alliance comes as demand for robotic-assisted surgery - in a market which CMR entered in 2014 - continues to grow, creating an opportunity to help healthcare providers expand robotic-assisted surgery programs with a scalable and practical solution. CMR Surgical's second-generation robot, the Versius Plus, was launched in December 2025, following the launch of the original product in 2019. In the last seven years the Versius has clocked up more than 45,000 surgical procedures globally across over 30 countries. It now has established clinical experience globally...

Keep reading with a free account

The rest of this article, and every signal for Stryker, is in your free account.

Extracted by Autobound

From the Signal API record
Event
Investment

What this signalsAn investment often shows where the company plans to grow.

Amount named
$400M
Takes effect
Oct 12, 2026
Financing type
Equity

Companies

  • CMR SurgicalRelated companycmrsurgical.com

More investment signals at other companies

The full record

From the Signal API record

Numbers

Amount named in the story
$400M

Extraction

Confidence
95%
Detected
Oct 12, 2026
signal_type
news
signal_subtype
invests_into

Use this data

Get every investment signal for Stryker and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Stryker this week?”

  2. Send it to your own tools

    The Signal API returns investment signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/abe0befe-4038-49b6-d7a8-0f8143f5c0c3 returns this record as JSON. POST /v1/companies/enrich returns every signal for stryker.com.

{
  "signal_id": "abe0befe-4038-49b6-d7a8-0f8143f5c0c3",
  "signal_type": "news",
  "signal_subtype": "invests_into",
  "detected_at": "2026-10-12T19:03:00+00:00",
  "company": {
    "name": "Stryker",
    "domain": "stryker.com"
  },
  "data": {
    "url": "https://www.cambridgeindependent.co.uk/business/stryker-invests-400m-in-cmr-surgical-and-could-buy-the-re-9486644/",
    "title": "Stryker invests $400m in CMR Surgical - and could buy the rest - Cambridge Independent",
    "excerpt": "Multinational US medical technologies company Stryker has invested $400million in the acquisition of exclusive US commercial rights to CMR Surgical’s Versius portfolio - with a further exclusive option to acquire the remaining equity at a later date. The sensational alliance means CMR Surgical’s established platform and robotics expertise will align with Stryker’s scale, customer relationships and commercial reach to accelerate growth of its Versius surgical robotic portfolio. The minority investment - CMR’s last official valuation was for $3billion in 2021 during a $600m Series D funding round led by SoftBank and Ally Bridge - means Stryker will serve as the exclusive US sales agent for the Versius portfolio, while CMR Surgical will continue to lead portfolio development and commercialisation in non-US markets. The alliance comes as demand for robotic-assisted surgery - in a market which CMR entered in 2014 - continues to grow, creating an opportunity to help healthcare providers expand robotic-assisted surgery programs with a scalable and practical solution. CMR Surgical’s second-generation robot, the Versius Plus , was launched in December 2025, following the launch of the original product in 2019. In the last seven years the Versius has clocked up more than 45,000 surgical procedures globally across over 30 countries. It now has established clinical experience globally...",
    "summary": "Stryker invested $400 million in CMR Surgical to acquire exclusive US commercial rights to the Versius surgical robotic portfolio, along with an option to buy the remaining equity.",
    "planning": false,
    "image_url": "https://www.cambridgeindependent.co.uk/_media/img/1GHL4DKPNNTR7BBBDW3V.jpg",
    "confidence": 0.95,
    "published_at": "2026-10-12T19:03:00Z",
    "effective_date": "2026-10-12",
    "article_sentence": "Multinational US medical technologies company Stryker has invested $400million in the acquisition of exclusive US commercial rights to CMR Surgical’s Versius portfolio - with a further exclusive option to acquire the remaining equity at a later date.",
    "amount_normalized": 400000000,
    "financing_type_tags": [
      "equity"
    ],
    "related_company_name": "CMR Surgical",
    "related_company_domain": "cmrsurgical.com"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.